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To the Editor:
We read with great interest the recently published article in the
Journal of Cardiology with the title of ‘‘Neutrophil gelatinase-
associated lipocalin (NGAL) in heart transplant recipients after
conversion to everolimus therapy’’ by Stypmann et al. [1]. The
authors prepared an outstanding study in the ﬁeld of heart
transplantation with the topic of NGAL-immunosuppressive
therapy in relation to heart transplantation. To our knowledge,
it is one of the best studies so far in the heart transplant ﬁeld,
however, the article raises some important points regarding this
study. It is essential to bear in mind that deterioration of blood
sugar and cholesterol regulation are continual metabolic compli-
cations after heart transplantation. Fasting blood glucose, hemo-
globin (Hb) A1c and lipid proﬁles [high-density lipoprotein (HDL),
low-density lipoprotein (LDL)] levels are suggested to be tested
during heart transplant follow up [2]. Several studies have
demonstrated that serum NGAL levels are positively correlated
to HbA1c and LDL, but negatively correlated to HDL in diabetic
patients [3,4]. We would like to emphasize that preexisting
diabetic nephropathy may mask the outcomes in this study
because these parameters may affect NGAL levels along with
immunosuppressive agents. We think that it would be more
reasonable if the authors had added the data of the above
mentioned suggestions, which will intensify their study. Finally,
we would like to conclude by congratulating Stypmann et al. [1] on
their outstanding study.
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Author’s reply
To the Editor:
We very much appreciate the favorable comments of Drs
Dolapoglu and Beketaev on our study [1]. We agree with them in
principle that the deterioration in blood sugar and cholesterol
metabolism, which is encountered in patients after heart
transplantation, might inﬂuence the results of neutrophil gelati-
nase-associated lipocalin (NGAL) determination in plasma and/or
urine. Therefore, we have determined fasting glucose and insulin in
study samples, calculated the Homeostatic Model Assessment
(HOMA)-Index, which is widely used for the estimation of insulin
resistance, and analyzed its relation to NGAL concentrations along
with body mass index (BMI), high-density lipoprotein-cholesterol
(HDL-C), and low-density lipoprotein cholesterol (LDL-C). None of
these parameters showed a signiﬁcant correlation with NGAL
levels in plasma or urine except for LDL-C, where borderline
signiﬁcant negative correlation with plasma NGAL (r = 0.106,
p = 0.068) has been noted. Our results are in concordance with
observations of Liu et al. [2], who found little evidence for the
association between plasma NGAL levels and metabolic param-
eters or cardiovascular risk factors such as LDL-C or HDL-C both
cross-sectionally and prospectively. The discrepancy between the
present and previous studies cited by Drs Dolapoglu and Beketaev
[3,4] may be related to the fact that these studies were performed
in populations with type 2 diabetes mellitus (T2DM). We have, reserved.
Letters to the Editor / Journal of Cardiology 66 (2015) 269–270270however, excluded T2DM patients requiring insulin treatment
from the investigated cohort, whereas the remaining diabetics
made up only 22% and 16% of heart transplant recipients receiving
everolimus or calcineurin inhibitors (CNI), respectively. Of note,
NGAL concentrations in plasma and urine remained signiﬁcantly
different between everolimus- and CNI-treated patients, when
T2DM subjects were left out of consideration [NGAL in plasma:
median (95% CI): 126 (94–171) ng/mL vs. 255 (224–298) ng/mL,
p < 0.001; NGAL in urine: median (95% CI): 6.5 (4.6–7.7) ng/g vs.
17.6 (10.5–26.9) ng/g creatinine, p < 0.001]. We fully agree with
Drs Dolapoglu and Beketaev that pre-existing diabetic nephropa-
thy might have had an impact on outcomes of our study. However,
the study was performed in a cross-sectional design and,
unfortunately, no information was available regarding parameters
reﬂecting metabolic status (insulin, HOMA index) or cardiovascular
risk (LDL-C, HDL-C) prior to the initiation of everolimus therapy.
Clearly, such parameters will have to be taken into account when
designing prospective observational studies assessing the utility of
NGAL as a marker of early kidney injury in patients who receive
post-transplant immunosuppressive therapy.
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